Melanotan-II's appetite suppression is stronger in rats on high-fat diets, independent of obesity
Background
The melanocortin system is a critical regulator of energy balance and food intake, but there is conflicting data on how its sensitivity changes with diet-induced obesity. It's unclear if the level of obesity itself or the specific composition of the diet is the primary driver of these changes. Understanding this relationship is crucial for developing effective anti-obesity therapies targeting this pathway. This study investigates the hypothesis that the fat content of a diet, rather than the degree of obesity, modulates the sensitivity of the melanocortin system to pharmacological intervention. The study uses Melanotan-II, an agonist for the melanocortin 3/4 receptors (MC3R/MC4R), to probe this sensitivity in rats fed different free-choice diets.
Study Design
Male Wistar rats were divided into four groups for 4 weeks: a standard chow (CHOW) diet, a free-choice high-fat/high-sugar diet (fcHFHS), a free-choice high-fat diet (fcHF), and a free-choice high-sugar diet (fcHS). After the diet period, melanocortin sensitivity was tested by administering the melanocortin 3/4 receptor agonist melanotan II (MTII) or a vehicle control directly into the lateral ventricle. The primary endpoint was the change in food intake. In a separate experiment, in situ hybridization was used to measure proopiomelanocortin (POMC) and agouti-related protein (AgRP) mRNA levels in the arcuate nucleus of rats after 4 weeks on these diets.
Results
After 4 weeks, only the fcHFHS diet group showed significant increases in caloric intake and body weight gain compared to the other groups (CHOW, fcHF, fcHS). Notably, body weight gain and caloric intake were comparable among the CHOW, fcHF, and fcHS groups. Despite the differences in diet and body weight, POMC and AgRP mRNA levels in the arcuate nucleus were not different between any of the diet groups. The key finding was in the response to MTII administration. The inhibitory effect of MTII on caloric intake was significantly larger in rats on the fcHF diet compared to the CHOW, fcHFHS, or fcHS groups.
Moreover, the analysis of macronutrient selection revealed that the fat component of the diet was the most inhibited by MTII, while the sugar component was the least inhibited.
This demonstrates that the anorectic effect of melanocortin agonism is highly dependent on dietary composition, specifically the presence of high fat, and is not a consequence of pre-existing obesity.
Key Findings
- MTII inhibited caloric intake to a larger extent in rats on a high-fat (fcHF) diet compared to chow, high-sugar (fcHS), or high-fat/high-sugar (fcHFHS) diets.
- Rats on the fcHF diet showed stronger food intake inhibition from MTII despite having comparable body weight gain and caloric intake to chow and fcHS groups.
- Following MTII administration, the intake of the dietary fat component was the most inhibited, while the sugar component was the least inhibited.
- After 4 weeks on the respective diets, levels of POMC and AgRP mRNA in the arcuate nucleus did not differ between any of the diet groups.
- Only the combined high-fat/high-sugar (fcHFHS) diet led to increased caloric intake and body weight gain over 4 weeks compared to the other diets.
Why It Matters
The findings suggest that the efficacy of melanocortin-based anti-obesity drugs like MTII may depend heavily on a user's macronutrient intake. For peptide users or clinicians, this implies that combining MTII with a high-fat, low-sugar diet could significantly enhance its appetite-suppressing effects, whereas a high-sugar diet might blunt them. This is a crucial consideration for protocol design, moving beyond simple caloric restriction to focus on macronutrient composition. The results decouple melanocortin sensitivity from obesity itself, pointing to dietary fat as a direct modulator of the pathway. While this is an animal study and far from a human protocol, it provides a strong rationale for investigating dietary interventions alongside melanocortin agonists to maximize therapeutic outcomes in weight management.
